ProCE Banner Activity

ASCEND-CML: Phase II Trial of Frontline Asciminib in Patients With CP-CML

Conference Coverage

The phase II ALLG CML13 ASCEND-CML trial demonstrated frontline asciminib to be safe and effective in patients with CP-CML, with early achievement of molecular response.

Released: December 14, 2023


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AbbVie Inc., AstraZeneca, Daiichi Sankyo, Inc., Merck Sharp & Dohme LLC, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc, and Seagen Inc.

AbbVie Inc.


Daiichi Sankyo, Inc.

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation

Regeneron Pharmaceuticals, Inc

Seagen Inc.